SCHEMBL2303307

SCHEMBL2303307

COc1cc(CC(=O)O)cc(F)c1F

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.54
TSHR P16473 2/20 0.54
ALDH1A1 P00352 1/20 0.54
NFKB1 P19838 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
CA5A P35218 1/20 0.48
HSD17B10 Q99714 2/20 0.42
PTGS1 P23219 1/20 0.42
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
CACNA1H O95180 2/20 0.40
SELL P14151 1/20 0.40
SELP P16109 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31610125 0.89 GAA (0.43) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL31048476 0.89 GAA (0.43) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL14430390 0.83 FFAR1 (0.50)
SCHEMBL908287 0.81 CES2 (0.46) GAATSHRNFKB1TDP1HSD17B10
SCHEMBL2126253 0.80 THRB (0.46) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL1096998 0.79 GAA (0.68) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL31409462 0.79 GAA (0.68) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL1036212 0.79 GAA (0.68) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL31103566 0.79 GAA (0.67) GAATSHRALDH1A1NFKB1TDP1
SCHEMBL8072165 0.79 GAA (0.67) GAATSHRALDH1A1NFKB1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed
EP-2349983-B1 DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES MERCK PATENT GMBH (DE) 2016-09-14 EP disclosed
EP-2349983-B1 DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES MERCK PATENT GMBH (DE) 2016-09-14 EP disclosed
US-8492440-B2 Difluorophenyldiacylhydrazide derivatives MERCK PATENT GMBH (DE) 2013-07-23 US disclosed
US-8492440-B2 Difluorophenyldiacylhydrazide derivatives MERCK PATENT GMBH (DE) 2013-07-23 US disclosed
US-8492440-B2 Difluorophenyldiacylhydrazide derivatives MERCK PATENT GMBH (DE) 2013-07-23 US disclosed
US-20110224302-A1 DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-15 US disclosed
US-20110224302-A1 DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-15 US disclosed
US-20110224302-A1 DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-09-15 US disclosed
EP-2349983-A2 DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES Merck Patent GmbH (DE) 2011-08-03 EP disclosed
WO-2010060522-A2 DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES MERCK PATENT GMBH (DE) 2010-06-03 WO disclosed
WO-2010060522-A2 DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES MERCK PATENT GMBH (DE) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS GAA 2015/4885TSHR 4177/4885ALDH1A1 4071/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS GAA 2385/4885TSHR 3993/4885ALDH1A1 3593/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS GAA 2385/4885TSHR 3993/4885ALDH1A1 3593/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS GAA 2385/4885TSHR 3993/4885ALDH1A1 3593/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS GAA 3456/4885TSHR 263/4885ALDH1A1 1854/4885
US-20110224302-A1 DIFLUOROPHENYLDIACYLHYDRAZIDE DERIVATIVES FGFR1, PKD1, AGTR1 GAA 2143/4885TSHR 115/4885ALDH1A1 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.